Brutalist Biotech

• PureTech shows durability of pulmonary fibrosis candidate deupirfenidone (11h)
• Schrödinger lays off 60 staffers amid ‘uncertain times and challenging economic conditions’ (13h)
• BioNTech pledges £1B to bolster UK presence while nabbing £129M grant from government (14h)
• Blueprint changes up $1.67B VantAI pact again, zeroing in on molecular glue potential (15h)
• SV Health’s latest pharma-backed dementia fund raises $269M to invest in new therapies (16h)
• RegenXBio cashes in $250M worth of payments for Zolgensma, 2 other gene therapies (20h)
• Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck (20h)
• Stars align for CRISPR Tx, Sirius as pair pen siRNA collab with a focus on thrombotic disease (21h)
• Tourmaline touts cardiovascular potential of former Pfizer antibody after phase 2 kidney disease win (1d)
• Prime Medicines CEO exits as biotech shelves sole clinical gene therapy, lays off staff (1d)

• FDA sets stricter approval standards for COVID vaccines (13h)
• Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (14h)
• Pfizer buys into PD-1/VEGF competition with 3SBio deal (15h)
• Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot (1d)
• Novavax’s COVID vaccine gets FDA approval, but with limits (1d)
• Regeneron wins bid to buy 23andMe out of bankruptcy (1d)
• FDA OKs first blood test to aid Alzheimer’s diagnosis (1d)
• How regulatory convergence is raising the bar for sterile drug safety—and how West leads the way (1d)
• From insight to impact: How eCOAs strengthen trial data quality (1d)
• Bridging the data gaps that impact retail and specialty-lite success (1d)

• Vinay Prasad makes first major imprint on FDA with new vaccine policy (9h)
• FDA adcomm votes against new indication for Genentech's cancer drug (9h)
• CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer (10h)
• RFK Jr. spars with senators over HHS budget and research cuts (11h)
• Future Covid vaccine approvals may narrow to older adults, high-risk people (14h)
• Tourmaline Bio's heart drug cuts inflammation as it seeks to compete with Novo, CSL's assets (14h)
• SV Health’s $269M dementia fund; Schrödinger lays off 7% of staff (15h)
• Trump administration reveals 'most favored nation' drug price country targets (15h)
• Weight loss startup Calibrate replaces CEO in leadership shakeup (16h)
• Optura raises $6.5M to help evaluate healthcare AI programs (16h)

• The Top 5 Most Active Corporate VCs in Pharma (7m)
• Evolving Market Pressures Force Biopharma Companies to Cut Assets Early (1h)
• FDA’s New Risk-Based Approach to COVID-19 Vaccines Aims to Ease ‘Public Distrust’: Makary, Prasad (9h)
• New Details From Trump’s Drug Pricing Effort Put Branded Drugs in the Crosshairs (14h)
• CRISPR Success in Single Baby Highlights Rare Disease 'Crisis' (14h)
• Pfizer’s China Deal Worth up to $6B Eclipses Peers in a Frenzied Market (14h)
• Prime Cuts 25% of Staff, Deprioritizes CGD Programs (15h)
• Understanding What Trump’s MFN Executive Order Can and Can’t Do (15h)
• CRISPR Expands Focus, Pays Up To $95M in Sirius' siRNA Pact (16h)
• Ionis Builds Triglyceride-Lowering Case for RNA-Targeting Tryngolza (16h)

Bio IT World

• Innovative Practices Winner: Chromatography Data Management (40m)
• Regeneron Acquires 23andMe for $256 Million (1d)
• Trends from the Trenches: Data, Discovery, Politics (6d)
• Sweden's PROMISE Initiative: Bridging Research and Healthcare Through Multi-Omics (1w)
• CFDE Unites Data Enthusiasts During Hackathon before Kick-Off of Bio-IT World Conference (1w)
• MiLabs Launches Platforma: Bridging the Gap Between Biology and Bioinformatics (2w)
• First-of-its-Kind AI Tool Reveals the ‘Social Network’ of Cancer Cells (2w)
• Illumina, Ovation Release GLP-1 Patient Dataset (2w)
• Illumina, Tempus AI Collaboration, CN Bio, Pharmaron Partnership, More (3w)
• PacBio Licenses New Methylation Tech for HiFi Sequencing, Will Deliver to Revio, Vega Systems (3w)

• Blunt Rochester presses RFK Jr. on CDC acting director (6h)
• New FDA framework on Covid vaccines leaves pediatricians confused and concerned (7h)
• RFK Jr. meets with health tech startups, most backed by Andreessen Horowitz (7h)
• Maryland governor signs law to expand powers of the state’s prescription drug affordability board (10h)
• Regeneron makes another deal — This one about AI (11h)
• Mental health apps can boost outcomes and lower costs, study finds (11h)
• Access to diabetes care in lower-income countries still lags for children, despite pharma efforts (14h)
• FDA will limit Covid vaccines to people over 65 or at high risk of serious illness, leaders say (14h)
• Trump administration lays out more details of plan to lower drug prices (15h)
• We’re reading about FDA eyeing PDUFA changes, compounded weight loss drugs, and more (16h)

• Valinor Discovery Launches to Simulate Drug Efficacy in Virtual Patients (1d)
• Dutch Startup CryoCloud Lands €2M to Automate Cryo-EM for Drug Discovery (1d)
• Kvantify Taps Gefion AI Supercomputer to Scale Quantum Chemistry Simulations for Drug Discovery (1d)
• Eligo Bioscience Gets $5M Grant to Advance Gene-Editing Skin Therapy Using Bacteria (1d)
• Absci Doses First Participants in Phase 1 Trial of AI-Designed Antibody for IBD (1d)
• Medable Updates Digital Platform With Oncology-Focused Tools Ahead of ASCO 2025 (1d)
• Researchers Use Terahertz Imaging for First-Ever 3D View of Cochlea Without Surgery (1d)
• CRISPR Therapy Saves Infant With Rare Genetic Disorder (1d)
• Oracle Rebuilds Its EHR Infrastructure to Support AI-Native Workflows (1d)
• Regeneron Acquires 23andMe Assets for $256M to Expand Consumer Genomics and Data-Driven Drug Discovery (1d)

• Seven lung cancer companies advancing new treatments in 2025 (16h)
• Will Europe become the new home for US researchers affected by policy shifts? (1d)
• Nine promising small molecule drug discovery companies to look out for in 2025 (4d)
• Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells (4d)
• Expert tips to choose the right CDMO for your biotech company (5d)
• The stem cell race for Parkinson’s disease: Recent studies show significant promise (6d)
• Nine biotech companies in Montreal to keep an eye on in 2025 (1w)
• Cracking the code: Delivering biotherapeutics successfully across EMEA (1w)
• Pharma giants pull back on AAV research: what’s next for the gene therapy space? (1w)
• The Netherlands’ biotech scene: The country sets its sights on becoming a global leader by 2040 (2w)

• Rapid Method for Cell Density Measurement Could Help Predict Tumor Response to Treatment (7h)
• ASGCT 2025: Gates Foundation “Doubling Down” on HIV Cure (15h)
• Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox (16h)
• Donor Heart Damage From Cold Storage May Be Prevented by Diuretic (17h)
• The News from New Orleans: GEN‘s Takeaways from ASGCT (17h)
• CellProthera Selects CELLforCURE by SEQENS for Phase III GMP Manufacturing (18h)
• Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits (1d)
• Why the Right Launch Strategy Can Get Biopharma from Clinical Breakthroughs to Commercial Blockbusters (1d)
• Biopharma is Mentally Ready, Yet Unprepared for AI Integration (1d)
• Regeneron to Acquire 23andMe with Winning $256M Bid (1d)

• Finding Meaning After an Acute Myeloid Leukemia Diagnosis (8h)
• Early Arterial Thrombosis May Signal Future Cancer Risk (9h)
• What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer? (10h)
• The Unnamed Nurse who Saved My Life During Breast Cancer (12h)
• Acoustic Cluster Therapy Shows Benefit in Colorectal Liver Metastases (13h)
• Prostate Cancer Treatment Options: Common Questions in Focal Therapy, Surgery (14h)
• With Cancer in Remission, What Is the New Normal for Patients? (16h)
• Younger Patients With Lung Cancer Often Have Targetable Biomarkers (1d)
• Facing Cancer as an AYA and Navigating Fertility Preservation Choices (1d)
• What Patients Should Know About a Melanoma Diagnosis (1d)

Contract Pharma*

• Regeneron in Deal to Acquire 23andMe for $256M (12h)
• Astoriom Expands Sample Stability Storage Services (12h)
• Fresenius Kabi Introduces Epinephrine Injection 30 mg per 30 mL Multi-Dose Vials (12h)
• NextCell, Fujifilm Irvine Scientific Enter Strategic Pact (13h)
• CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing (14h)
• CS Analytical Laboratory Opens Package Distribution Testing Service Expansion (15h)
• Shift Bioscience Announces Board and Advisor Appointments (15h)
• Zealand Pharma Appoints Chief Development Officer (1d)
• GC Biopharma Partners with Körber to Implement MES (1d)
• Cellino’s iPSC Manufacturing Technology Receives FDA AMT Designation (1d)

• FDA approves Amneal’s self-administered migraine drug Brekiya (18h)
• MHRA approves guselkumab for Crohn’s disease and ulcerative colitis (1d)
• Massalia Therapeutics launches to advance novel treatments for complex conditions (1d)
• AviadoBio opens UK trial for FTD gene therapy (5d)
• Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease (6d)
• Kaerus Bioscience secures orphan drug designation for fragile x syndrome treatment (6d)
• Rein Therapeutics initiates renew phase 2 trial for IPF treatment (1w)
• Apiary invests in life sciences marketing specialist performance-io (1w)
• Amgen’s Tepezza granted marketing authorisation in the UK (2w)
• iOnctura starts randomised phase 1/2 trial in lung cancer treatment (2w)

• How a New PE-Backed RCM Company Plans to Fix the ‘Transactional Bowels of US Healthcare’ (1h)
• 3 Health Investors Share Their Most Controversial Industry Takes (2h)
• How a Tiny Federal Agency Supports Innovation & Competitiveness in the Scientific Community (2h)
• Payments Simplified: The 4 Key Features of Modern Healthcare Payment Platforms (15h)
• The Changing Landscape of Ransomware: Why Healthcare Organizations Are Paying Less (16h)
• The Role of Consultants in Tackling Healthcare Expenses (16h)
• 23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron’s Gene-Based Drug R&D Efforts (1d)
• How One Company Aims to Save Lives with Its Smartwatch (1d)
• How One Startup Is Standing Out in the Crowded AI Scribe Market (1d)
• Why Agentic AI Is Not Quite Ready for Primetime in Healthcare (1d)

• Editorial: Venture capital still likes cleantech (12h)
• A guide to navigating AI chemistry hype (13h)
• Federal policy changes spell turmoil for biopharma (15h)
• Global pandemic treaty nears adoption, but key obstacle remains (1d)
• ACS puts the spotlight on chemical technical professionals (1d)
• Comment: Why attend ACS Fall 2025? (1d)
• Mercury emissions are falling (1d)
• Flu virus transcription caught in the act (4d)
• AI start-up raises $11 million to make drug formulations better (4d)
• A baby gets the world’s first personalized CRISPR therapy (4d)

The Pharma Letter*

• Grünenthal appoints Maren Thurow to lead global comms (13h)
• HHS, CMS set Most-Favored-Nation pricing targets (13h)
• Australia’s digital health sector growing as global funding surges (13h)
• CEO among 25% of staff out the door at cash-strapped Prime (14h)
• Apnimed touts Phase III success for first-ever sleep apnea pill (14h)
• BioNTech expands partnership with UK govt, pledging £1 billion investment (15h)
• Pfizer strikes $6 billion deal with 3SBio for cancer drug rights (16h)
• New $35 million partnership to advance blood disorder therapies (16h)
• IL-5 biologics well-positioned to expand respiratory reach, analyst says (18h)
• IL-5 biologics well-positioned to expand respiratory reach, analyst says (18h)

• CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL (8h)
• ODAC Votes Daratumumab Benefits Smoldering MM (8h)
• Unmet Needs and Therapy Modifications Relevant in the CRC Landscape (10h)
• Myeloma Research Sees Transformation Following ODAC Support For MRD End Point (11h)
• The Importance of Global Collaboration in Oncology: Li's View (12h)
• FDA Oks Phase 3 Trial of PT-112 in mCRPC Following Successful EOP2 Meeting (12h)
• 2025 ASCO Annual Meeting: The Show and After Show (12h)
• ODAC Votes STARGLO Trial Not Applicable to US Patients With DLBCL (13h)
• AI Predicts Prostate Cancer Prognosis Fairly Across Races (13h)
• Clinical Trial Awareness Day: Progress in Brain Cancer Research (14h)

• Zealand Pharma appoints new development chief with experience from Novo Nordisk and FDA (15h)
• China will provide extra support to WHO (16h)
• Regeneron acquires US biotech firm (18h)
• Over 100 countries vote for global pandemic agreement (20h)
• Pfizer licenses 3SBio cancer drug for record USD 1.25bn (20h)
• Novo Nordisk needs a new CEO: Headhunter gives three bids for Fruergaard's replacement (1d)
• China becoming largest contributor to WHO: "Life goes on without the Americans" (1d)
• FDA approves blood test for diagnosing Alzheimer's (1d)
• Foundation behind Eli Lilly is now the largest in the US (1d)
• Novo Nordisk should consider finding CEO in the US, analysts say (1d)

• Autoimmune Disease, Transformed? (10h)
• Lose Your Crystalline Form and Go Amorphous (1d)
• Alzheimer's Update: Infectious Agents and Gamma-Secretase Too (5d)
• Obesity Without Metabolic Dysfunction? (6d)
• New Cell Therapy For Resistant Hodgkins Patients (1w)
• Escape From the Lysosome (1w)
• Heavy Water in Your NMR Experiments, And Elsewhere (2w)
• GIPR: Agonists and Antagonists Do the Same Thing, But How (2w)
• Mutant Proteins Classified (2w)
• The Continuing Crisis, Part XIV: The Trumpist Worldview (2w)

• O'Shaughnessy says UK clinical trials sector is on the mend (17h)
• Imec showcases ingestible sensor for gut studies (18h)
• UK's long-term R&D investment policy welcomed (19h)
• Pfizer snaps up PD-1/VEGF drug from China's 3SBio (20h)
• Regeneron swoops on genetic testing firm 23andMe (1d)
• Japan follows UK in GSK's comeback tour for Blenrep (1d)
• Partner of ex-Theranos CEO raising cash for testing start-up (1d)
• BioMarin starts rebuilding after its downsizing spree (1d)
• FDA finally okays Novavax's COVID-19 jab, with restrictions (2d)

• We need international partnerships to get new cancer drugs into the clinic (15h)
• Gene-based vaccine shows promise in early-stage trial (16h)
• First patient receives personalised CRISPR gene editing therapy (18h)
• First patients dosed in final cohort of Phase Ib Parkinson’s disease trial (21h)
• Tipping point in Huntington’s disease research (21h)
• Webinar: Rapid, comprehensive AAV genomic profiling made simple (21h)
• Novel GPR119 agonist shows promise in treating MASH and Type 2 diabetes (1d)
• More efficient next-gen obesity clinical trials needed, says survey (1d)
• SMC okays Pedmarqsi to prevent cisplatin-induced hearing loss (1d)
• New DDW Highlights podcast: 19 May 2025 (1d)

Google News Biotech

• Viewpoint: Activist-critics of GMO crops claim falsely that biotechnology increases chemical use in farming - Genetic Literacy Project (1h)
• Russian Pharmaceutical Market Projected to Reach $10.5 Billion in Generics by 2025 Amid Biotech Growth - geneonline.com (1h)
• Biotech Stocks Fluctuate as Trump Administration Tariff Reversal Impacts Market Value - geneonline.com (1h)
• Biotech Breakfast + Office Hours - Foley & Lardner LLP (6h)
• Biotech Panel Discussion & Happy Hour - Foley & Lardner LLP (6h)
• 23andMe acquired by biotech giant Regeneron after bankruptcy filing - FOX 7 Austin (7h)
• 23andMe acquired by biotech giant Regeneron after bankruptcy filing - LiveNOW from FOX (7h)
• 23andMe acquired by biotech giant Regeneron after bankruptcy filing - FOX 26 Houston (7h)
• PCI BIotech: Disclosure of voting rights for Chair of the Board - The Manila Times (9h)
• PCI BIotech: Disclosure of voting rights for Chair of the Board - GlobeNewswire (9h)